Mona Alshahawey1, Sara M Shaheen2, Tamer Elsaid3, Nagwa Ali Sabri1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Monazamet El-Wehda El-Afriqeya St., Abbassia, Cairo, Egypt. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Monazamet El-Wehda El-Afriqeya St., Abbassia, Cairo, Egypt. drsara61181@gmail.com. 3. Department of Nephrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Abstract
PURPOSE:Oxidative stress, which is most likely a key mediator in the development of cardiovascular disease, is implicated in the progression and deterioration of chronic kidney disease. Patients on hemodialysis exhibit the excessive generation of oxidative stressors, which may also be responsible for the endothelial dysfunction prevalent in these patients. Febuxostat, an inhibitor of xanthine oxidase enzyme, is emerging as a novel drug in the amelioration of oxidative stress status. However, studies regarding its effect among hemodialysis patients are still lacking. METHODS: This prospective, block-randomized, double-blinded, placebo-controlled study was carried out to assess the effect of oral 40 mg febuxostat on oxidative stress in hemodialysis patients. In total, fifty-seven eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. Serum malondialdehyde (MDA) and serum superoxide dismutase (SOD) were assessed at baseline and at the end of the study. A correlation analysis between previously reported serum asymmetric dimethylarginine (ADMA), serum MDA and serum SOD was performed. RESULTS:Febuxostat significantly decreased the serum MDA and significantly increased the serum SOD, while no significant results were observed in the placebo group. A highly positive correlation between the MDA levels and ADMA levels at baseline was noticed in both groups, while there was a highly negative correlation between the SOD levels and ADMA levels at baseline in both groups. A positive correlation between the change in ADMA levels and MDA levels from baseline was observed only in the drug group. CONCLUSION:Febuxostat appears to have a direct ameliorating effect on oxidative stress in hemodialysis patients with endothelial dysfunction.
RCT Entities:
PURPOSE: Oxidative stress, which is most likely a key mediator in the development of cardiovascular disease, is implicated in the progression and deterioration of chronic kidney disease. Patients on hemodialysis exhibit the excessive generation of oxidative stressors, which may also be responsible for the endothelial dysfunction prevalent in these patients. Febuxostat, an inhibitor of xanthine oxidase enzyme, is emerging as a novel drug in the amelioration of oxidative stress status. However, studies regarding its effect among hemodialysis patients are still lacking. METHODS: This prospective, block-randomized, double-blinded, placebo-controlled study was carried out to assess the effect of oral 40 mg febuxostat on oxidative stress in hemodialysis patients. In total, fifty-seven eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. Serum malondialdehyde (MDA) and serum superoxide dismutase (SOD) were assessed at baseline and at the end of the study. A correlation analysis between previously reported serum asymmetric dimethylarginine (ADMA), serum MDA and serum SOD was performed. RESULTS:Febuxostat significantly decreased the serum MDA and significantly increased the serum SOD, while no significant results were observed in the placebo group. A highly positive correlation between the MDA levels and ADMA levels at baseline was noticed in both groups, while there was a highly negative correlation between the SOD levels and ADMA levels at baseline in both groups. A positive correlation between the change in ADMA levels and MDA levels from baseline was observed only in the drug group. CONCLUSION:Febuxostat appears to have a direct ameliorating effect on oxidative stress in hemodialysis patients with endothelial dysfunction.
Authors: F Locatelli; D Marcelli; F Conte; M D'Amico; L Del Vecchio; A Limido; F Malberti; D Spotti Journal: Nephrol Dial Transplant Date: 2000 Impact factor: 5.992
Authors: Mary C Corretti; Todd J Anderson; Emelia J Benjamin; David Celermajer; Francois Charbonneau; Mark A Creager; John Deanfield; Helmut Drexler; Marie Gerhard-Herman; David Herrington; Patrick Vallance; Joseph Vita; Robert Vogel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: Wolfram Doehner; Nina Schoene; Mathias Rauchhaus; Francisco Leyva-Leon; Darrell V Pavitt; David A Reaveley; Gerhard Schuler; Andrew J S Coats; Stefan D Anker; Rainer Hambrecht Journal: Circulation Date: 2002-06-04 Impact factor: 29.690
Authors: GianMario Gerardi; Mario Usberti; Giuliana Martini; Alberto Albertini; Lidia Sugherini; Alfonso Pompella; Lorenzo Diego Di Journal: Clin Chem Lab Med Date: 2002-02 Impact factor: 3.694
Authors: H Trimarchi; M R Mongitore; P Baglioni; M Forrester; E A R Freixas; M Schropp; H Pereyra; M Alonso Journal: Clin Nephrol Date: 2003-06 Impact factor: 0.975
Authors: Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: J Scott McNally; Michael E Davis; Don P Giddens; Aniket Saha; Jinah Hwang; Sergey Dikalov; Hanjoong Jo; David G Harrison Journal: Am J Physiol Heart Circ Physiol Date: 2003-09-04 Impact factor: 4.733